LFMD

$3.98

Pre-MarketAs of Mar 23, 8:00 PM UTC

LifeMD, Inc.

OverviewIntradayAnalysisPROIntelligencePROAsk AIPROTranscriptsPROStatementsPRO

Historical Price

Price (Line)
50-Day SMA
200-Day SMA
Synthesizing Whystock Narrative...
Loading Financials...

Peer Comparison

JNJUNHPFE

Whystock Valuation Model

Calculated using a trailing P/E relative model adjusted by sector ROE and historical growth.
Current Price$3.98
Potential Upside
5%
Whystock Fair Value$4.18
Price
UndervaluedFair ValueOvervalued

Fundamentals

SectorHealthcare
IndustryHealth Information Services

LifeMD, Inc. operates as a direct-to-patient telehealth company that connects consumers to healthcare professionals for medical care in the United States. The company operates through two operating segments: Telehealth and WorkSimpli. The company off...

Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$191.58M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
2.01
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROIC
Average efficiency. Growth may require heavy reinvestment.
-610.27%
Quick Ratio
Tight liquidity. Monitor cash flow carefully against debt.
0.66

Recent News

Zacks
Mar 23, 2026

Are GLP-1 Drugs Becoming a Meaningful Revenue Driver for CAH Stock?

CAH sees GLP-1 drugs boost revenue growth, but margins lag as strong demand lifts volumes without significantly improving profitability.

BEARISH
Negative press. News cycle fixated on risk factors or misses.
Zacks
Mar 23, 2026

Hims & Hers Expands Integrated Digital Healthcare Ecosystem

HIMS builds a seamless digital healthcare ecosystem, expanding into diagnostics, global markets and specialty care to reshape access and delivery.

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Simply Wall St.
Mar 20, 2026

How The LifeMD (LFMD) Story Is Shifting On GLP‑1 Growth And Higher 2026 Targets

LifeMD’s updated analyst narrative centers on a revised fair value estimate, with the price target moving from US$9.25 to US$9.88, a shift of around 7%. Analysts link this change to Q4 revenue and adjusted EBITDA beats, a stronger 2026 outlook, and growing interest in LifeMD’s virtual care push around weight loss management and GLP-1 exposure. As you read on, you will see how these moving pieces are shaping the story and what to watch as the narrative continues to evolve. Stay updated as the...

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Simply Wall St.
Mar 13, 2026

A Look At LifeMD (LFMD) Valuation After Profitability Return And 2026 Growth Guidance

LifeMD (LFMD) is back on investors’ radar after reporting Q4 and full year 2025 earnings, swinging to net income and pairing those results with fresh 2026 revenue guidance and product expansion updates. See our latest analysis for LifeMD. That earnings swing and new 2026 guidance have come after a sharp rebound in the share price, with a 31.17% 7 day share price return and 29.02% 30 day share price return, even though the 1 year total shareholder return remains down 30.48%. If LifeMD’s recent...

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
GuruFocus.com
Mar 10, 2026

LifeMD Inc (LFMD) Q4 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic ...

LifeMD Inc (LFMD) reports robust financial performance with a 25% annual revenue increase and strategic advancements in AI and healthcare services.

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.